In the last decade, the discovery of sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) [16] has revolutionized DKD management [17]. Here, SLC5A2 is linked to diabetic kidney disease.